We and others have previously found that patients with an elevated risk for developing BP i.e., those with neurological disorder such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, have an increased prevalence of BP180 autoantibodies (27–30). This evidence concerns the gene COL17A1 and early-onset autosomal dominant Alzheimer disease.